Jaguar Health, Inc. current report, 18 August 2022

Full document

Jaguar Health, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on August 23, 2022, covering events that occurred on August 18, 2022. The filing details a private placement transaction and related amendments to existing agreements with SynWorld Technologies Corporation ("SynWorld").

Key Financial Metrics and Transaction Details

  • Transaction Type: Private placement of Series E Preferred Stock.
  • Gross Proceeds: $100 (from the sale of 10 shares).
  • Price Per Share: $10.00 (Series E Original Issue Price).
  • Liquidity: No established trading market exists for the Series E Preferred Stock; liquidity is expected to be limited.
  • Financial Statements: This filing does not contain revenue, profit, cash flow, or debt metrics for the company's operations.

Material Changes and Agreements

The filing reports two primary material agreements entered into on August 18, 2022:

  1. Securities Purchase Agreement: Jaguar Health issued 10 shares of Series E Preferred Stock to SynWorld. These shares rank senior to Common Stock regarding liquidation distributions.
  2. First Amendment to License and Services Agreement: As consideration for the preferred shares, the Company amended its June 28, 2022 agreement with SynWorld. Key changes include:
    • Service Share pricing set to a minimum of $0.25 per share (if issued within six months) or $0.31 per share (if issued after six months).
    • Implementation of a 90-day lock-up period on Subscription Shares and Service Shares issued to SynWorld.

Terms of Series E Preferred Stock and Outlook

The Series E Preferred Stock carries specific rights and obligations designed to facilitate a corporate action:

  • Voting Rights: The stock has no general voting rights but grants 750,000,000 votes per share specifically for the "Authorized Shares Increase Amendment" (increasing authorized Common Stock from 150 million to 298 million). These votes must be cast in the same proportion as Common Stock votes.
  • Liquidation Preference: Holders are entitled to the Series E Original Issue Price ($10.00) per share before any payment to Common Stockholders in a liquidation or change of control event.
  • Dividends: No dividends are payable on the Series E Preferred Stock.
  • Mandatory Redemption: The Company must redeem the shares no later than the 3rd business day following the stockholder vote on the Authorized Shares Increase Amendment, at a price equal to the liquidation amount.
  • Regulatory Status: The issuance was made pursuant to exemptions under Section 4(a)(2) and/or Rule 506(b) of Regulation D.

Investor Verification Checklist

  • Verify the outcome of the Special Meeting of stockholders regarding the Authorized Shares Increase Amendment.
  • Confirm the date of mandatory redemption for the Series E Preferred Stock following the stockholder vote.
  • Review the full text of the Certificate of Designation (Exhibit 3.1) for complete terms and the Certificate of Correction filed on August 22, 2022.
  • Assess the impact of the 90-day lock-up period on future share issuances to SynWorld under the amended License Agreement.
  • Note that the $100 proceeds from this transaction are nominal and do not reflect the company's broader operational liquidity or cash position.